Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity

Andrea Ravelli, James M. Reuben, Francesco Lanza, Simone Anfossi, Maria Rosa Cappelletti, Laura Zanotti, Angela Gobbi, Manuela Milani, Daniele Spada, Paolo Pedrazzoli, Massimo Martino, Alberto Bottini, Daniele Generali

Research output: Contribution to journalArticlepeer-review


Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.

Original languageEnglish
Pages (from-to)689-702
Number of pages14
JournalExpert Review of Anticancer Therapy
Issue number6
Publication statusPublished - Jun 1 2015


  • adoptive T-cell therapy
  • breast cancer
  • breast cancer therapy
  • breast cancer vaccine
  • immune checkpoint blockade
  • ipilimumab
  • pidilizumab
  • tremelimumab
  • vaccination

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Immune-related strategies driving immunotherapy in breast cancer treatment: A real clinical opportunity'. Together they form a unique fingerprint.

Cite this